$AEYE

AudioEye Reports Record Second Quarter 2026 Results

AudioEye (Nasdaq: AEYE) reported Q2 2026 results for the quarter ended June 30, 2026. ARR rose to $42.3M from $41.2M sequentially and 11% YoY. Revenue increased 9% to $10.7M. Adjusted EBITDA was $3.0M. The company raised full-year adjusted EBITDA guidance and expects Q3 revenue $10.85M-$11.05M.

Original reporting
Published Aug 13, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AudioEye Reports Record Second Quarter 2026 Results — source image
Decision brief

The 30-second read

$AEYEBullishHigh
01

Why it matters

This quarter’s key trading inputs are the raised full-year adjusted EBITDA guidance, the stated target for annualized run-rate adjusted EBITDA by year-end, and the Q3 and full-year revenue/adjusted EPS ranges.

02

Market read

A fresh earnings and guidance update with explicit profitability and cash-flow targets, plus a CFO transition and an accessibility index update.

03

What to watch

The guidance is expressed in adjusted metrics; traders may discount GAAP loss trajectory and scrutinize free cash flow sustainability in the second half rather than relying on adjusted EBITDA alone.

Relevance 9/10Novelty 9/10Timing: after-hours today, ahead of the 4:30 p.m. ET earnings call

Background

AudioEye is a digital accessibility company providing monitoring and automated testing/fixes, and it also publishes an annual Digital Accessibility Index.

Company-level read

Ticker impact

$AEYEBullishMedium confidence
Context

AudioEye reported Q2 2026 results and raised full-year adjusted EBITDA guidance, targeting over $15M annualized run-rate by year-end.

Expected impact

Likely positive bias for the next trading session, with follow-through dependent on investor reaction to the raised EBITDA and 2H free cash flow emphasis.

Evidence & confidence

The release includes multiple forward-looking datapoints (raised adjusted EBITDA guidance, full-year adjusted EPS floor, and Q3 revenue/EBITDA ranges) that directly affect valuation and positioning for a small-cap growth name.

Market effects

Supports the digital accessibility software theme by highlighting improving margins and litigation expense normalization, which may influence sentiment toward accessibility compliance vendors.

No clear regional spillover beyond US-listed small-cap tech sentiment.

Limited, though the Digital Accessibility Index includes US and Europe scanning results that may reinforce demand narratives for cross-border compliance.

Counterpoint

Operating expenses rose 23% and litigation expenses increased; the EBITDA improvement may be partly offset by ongoing legal cost volatility and stock-based compensation adjustments.

Key entities

  • AudioEye, Inc.

    Nasdaq-listed digital accessibility provider reporting Q2 2026 results and raising full-year adjusted EBITDA guidance.

  • Kelly Georgevich

    CEO who stated the company is raising adjusted EBITDA guidance and evaluating capital deployment options.

  • Matthew Domeyer

    Appointed CFO effective July 2026, succeeding Kelly Georgevich.

Related articles

$AEYEMed

AUDIOEYE INC (AEYE): Results of Operations and Financial Condition

AUDIOEYE INC (AEYE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aeye-20260813xex99d1.htm EX-99.1 ​ ​ Exhibit 99.1 ​ AudioEye Reports Record Second Quarter 2026 Results Forty-Second Consecutive Period of Record Revenue TUCSON, Ariz. — August 13, 2026 — AudioEye, Inc. (Nasdaq: AEYE) (“AudioEye” or the “Company”) , an industry-leading

$LFTMed

Lument Finance Trust, Inc. (LFT): Results of Operations and Financial Condition

Lument Finance Trust, Inc. (LFT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 tm2623066d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 August 2026 Lument Finance Trust Q2 2026 Earnings Supplemental Disclaimer 2 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

$TILMed

Instil Bio, Inc. (TIL): Results of Operations and Financial Condition

Instil Bio, Inc. (TIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q2-26er.htm EX-99.1 Document Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing in

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Results of Operations and Financial Condition

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 3 d48818dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of August 13, 2026, by and among MapLight Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each of the purcha

$RNAMed

Atrium Therapeutics, Inc. (RNA): Results of Operations and Financial Condition

Atrium Therapeutics, Inc. (RNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular col

$CLDIMed

Calidi Biotherapeutics, Inc. (CLDI): Results of Operations and Financial Condition

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a firs